William (Bill) Wade

Hivemind is a fractional IT consulting and expert matching platform built for small to mid-sized businesses and startups that need trusted, flexible expertise to modernize technology, migrate to the cloud, enhance security, or implement Al without the cost and risk of traditional consulting firms. Through Al driven matching and collaborative swarm models, Hivemind connects companies with vetted experts and curated teams who can deliver outcomes quickly and transparently. Unlike generic freelancer marketplaces, Hivemind focuses on quality, credibility, and collaboration, ensuring the right expert is aligned to the right project every time. For experts, Hivemind provides access to meaningful opportunities, career building tools, education and upskilling programs, and the ability to collaborate with peers on larger, more impactful projects all without the overhead of running a boutique agency or being tied down to a full-time employer. Hivemindd is a community where experts control their careers and businesses solve bigger problems faster. Website www.hivemindd.com

nForce AI is a women-owned (WOSB SBA Certified) AI solutions company, specializing in data-graph RAG (zeo Hallucination) application deployment, Anomaly Detection & Fraud Prevention. nForce transforms complex data environments into streamlined, AI-ready ecosystems powered by our autonomous knowledge graph engine, delivering error-free outputs, real-time insights, and transparent data origins. Beyond technology, we empower Federal government agencies, state and local governments, and their prime contractors, as well as private sector enterprises and financial institutions, through tailored AI solutions, workforce enablement, and AI training and certification programs. We provide responsible AI thought leadership consulting and engage public and private communities alike, equipping teams to detect fraud, manage AI responsibly, and maximize outcomes with confidence.

I’m pleased to share that I have accepted a role as Senior Advisor & Board Observer at Croton Healthcare. I’ll be working closely with the Croton Board of Managers and the senior management of its subsidiary, MEGIN, to support strategic initiatives, governance, and long-term growth of the company — helping accelerate adoption of MEGIN’s cutting-edge magnetoencephalography (MEG) technology for improved neurological diagnostics and care. MEGIN is globally recognized for its leadership in MEG, a non-invasive functional brain imaging solution being used worldwide to diagnose and inform treatment for epilepsy, brain tumors, autism, Alzheimer’s, vascular malformations, traumatic brain injury/concussion and other neurological disorders. MEGIN strongly aligns with my own commitment to advancing healthcare through technology and responsible stewardship.

Oscillo Biosciences is a neurotechnology company developing medical devices and digital therapeutic platforms to treat serious neurodegenerative diseases like Alzheimer's Disease, Parkinson's, aphasia, and dyslexia. Currently more than 23 million Americans and 55 million adults worldwide suffer from Alzheimers and dementia rising at an alarming rate of 10 million annually. Alzheimer’s disease is the 5th leading cause of death among Americans age 65 and older. Among the top 10 causes of death, it is the only one for which there is no known cure. Alzheimer's disease requires extensive medical care, including diagnosis, treatment, and ongoing management. The cost of healthcare services for Alzheimer's patients is substantial, straining healthcare systems in large countries. For instance, the estimated annual cost of Alzheimer's disease in the United States in 2022 was $321 billion. This cost is expected to increase to more than $1 trillion by 2050 making it the most expensive disease in the United States This cost includes Medicare and Medicaid expenses, hospital visits, and prescription medications. Our approach is predicated on the understanding that brain rhythms supporting memory and cognition are disrupted in people with Alzheimer’s disease. Oscillo Biosciences has developed a non-invasive medical device and accompanying digital therapeutic platform that works by synchronizing specialized light pulses with familiar music to rhythmically stimulate the brain at targeted frequencies. This produces changes in the brain at a molecular level, including reduction of key pathological proteins (Aβ and Tau) and improved neural connectivity. Our technology is protected by US patents No's: 11,730,975, 11,508,393, 8,930,292, 7,376,562 and 8,583,442 to Oscilloscape and International patents 2,529,369 (EU), 1,774,514 (EU), and 5,864,441 (Japan)

Exciting times ahead as I continue my journey with the incredible Vastly team, formerly known as Company.com! At Vastly, we're on a mission to redefine digital experience solutions, transforming the way organizations approach digital transformation. Our comprehensive suite of solutions empowers organizations (public and private sectors) to achieve their goals with reduced risk, minimized costs, and accelerated time to value. We specialize in end-to-end Enterprise Product Development Solutions, tackling the toughest challenges in today's dynamic business landscape. Our approach is marked by expert strategic advisory, seamless execution through our talented teams, and leveraging cutting-edge tools and technology. Follow my profile to stay updated on the latest trends, insights, and innovations driving digital experience solutions. Let's revolutionize together! #Vastly #DigitalTransformation #InnovationUnleashed #SOLaaS

Soccol IP has partnered with more than 25 companies over several decades, providing investment and advisory services that fuel innovation, accelerate growth, and unlock technology-driven transformation. Our work spans a diverse set of industries, from fintech, payments, and B2B services to real estate, biotech, AI/ML, cybersecurity, data security and compliance, social media, analytics, social gaming, and e-commerce. As a trusted advisor to boards, CEOs, and founders, Soccol IP brings a unique combination of strategic foresight, operational insight, and deep sector expertise. We help emerging and established companies alike navigate complex markets and execute with clarity—from biotech and medtech pioneers advancing patient outcomes, to AI developers reshaping industries, to startups building digital experiences, interactive design platforms, recruitment technologies, and next-generation distribution models. At the center of our work is a commitment to AI technology innovation, helping companies harness machine learning, automation, and data-driven intelligence to transform industries and create lasting competitive advantage. Alongside this, Soccol IP plays an active role in advancing fintech solutions that redefine commerce and payments, and in strengthening talent recruitment platforms that power the next wave of workforce transformation. Our portfolio also extends across advanced manufacturing, medical devices, digital health, and consumer health platforms such as activity and wellness tracking apps. Across each sector, Soccol IP is recognized for guiding leaders with seasoned perspective, actionable planning, and a relentless focus on positioning companies for lasting success in competitive markets.

Breezio is a Collaborative Research Platform that empowers researchers to tap into the collective intelligence of other researchers who are working on the same problems or projects. Breezio’s mission is to serve researchers by helping them accelerate discoveries by bringing experts together to solve some of the world biggest problems. Together we’ll achieve breakthrough collaborations! Our team has spent the last twenty years building communities and developing robust collaboration platforms for hundreds of thousands of people worldwide. We’ve learned a lot about how teams work best together and the tools necessary to break down the barriers so communities may collaborate effectively.

Collaborative Research Platform. Breezio’s mission is to serve researchers by helping you accelerate discoveries by bringing experts together to solve some of the world biggest problems. Together we’ll achieve breakthrough collaborations. Breezio helps research teams discover experts, publish articles, and collaborate around all forms of content through annotations, discussions, web-conferencing and much more, empowering your institute to accelerate the pace of innovation. Research teams may be as private or open as you like.

Oscillo Biosciences is a pre-commercial neurotechnology company developing medical devices and digital therapeutic platforms to treat serious neurodegenerative diseases like Alzheimer's Disease, Parkinson's, aphasia, dyslexia and others. Currently more than 6 million Americans suffer from dementia due to AD and the incidence is rising at an alarming rate. Alzheimer’s disease is the 5th leading cause of death among Americans age 65 and older. Among the top 10 causes of death, it is the only one for which there is no known cure. Alzheimer's disease requires extensive medical care, including diagnosis, treatment, and ongoing management. The cost of healthcare services for Alzheimer's patients is substantial, straining healthcare systems in large countries. For instance, in the United States, Alzheimer's disease is estimated to cost over $305 billion annually, making it the most expensive disease in the country (Alzheimer's Association, 2021). This cost includes Medicare and Medicaid expenses, hospital visits, and prescription medications. Our approach is predicated on the understanding that brain rhythms supporting memory and cognition are disrupted in people with Alzheimer’s disease. Recent studies have proven that stimulating brain waves at specific frequencies can bring about changes at the molecular level, diminishing brain plaques, untangling neural networks, and improving memory and cognition. Oscillo Biosciences has developed a non-invasive medical device and accompanying digital therapeutic platform that works by synchronizing specialized light pulses with familiar music to rhythmically stimulate the brain at targeted frequencies. This produces changes in the brain at a molecular level, including reduction of key pathological proteins (Aβ and Tau) and improved neural connectivity. Our technology is protected by US patents No's: 11,730,975, 11,508,393, 8,930,292, 7,376,562 and 8,583,442 to Oscilloscape, LLC; other US and International patents pending.

Founded in 2008, Company.com offers a unique Digital Experience Platform (DXP) that specializes in reducing time-to-value of integration, modernization and digital transformation initiatives. By building connected experiences that are technology-agnostic via micro-architecture and developer-friendly tools, the Company.com DXP allows businesses to deliver the value of a modern digital platform regardless of the challenges they face with their legacy infrastructure. Implementation use-cases include B2B ecommerce; customer and partner portals; intranets; headless APIs; and more. For more information on Company.com, please visit www.govastly.com (new brand effective Q4 2023)

Internet social games and internet real money gaming platform (International only in countries that permit online gaming to licensed operators). GNS develops niche P-to-P games that are most popular in specific regions around the world. The first product developed and launched is the Phillipines nation game favorite Tong-its. Before its sale in 2021, social tongits was the largest social game platform for Tong-its in the world with over 700,000 registered active users. GNS was granted a 15-year exclusive real money gaming license in 2013 through North Cagayan Gaming & Amusement Corporation, Phillipines for world wide player-to-player Tong-its.

Recruited by Marriott into the Marriott Executive Management program in 1982 - left UNH for this learning opportunity in VA/MD.